Company news

Viridian Therapeutics, Inc. news in 2023

Viridian Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease

December 17, 2023

Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference

November 20, 2023

Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 12, 2023

Viridian Therapeutics to Participate in the Jefferies London Healthcare Conference

November 7, 2023

Viridian Therapeutics Announces Encore Presentations at the 2023 Annual Meeting of the American Academy of Ophthalmology

November 2, 2023

Viridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs and Announces $185 Million Private Placement Financing

October 29, 2023

Viridian Therapeutics Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Subcutaneous Drug Delivery in Thyroid Eye Disease

October 25, 2023

Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors

September 24, 2023

Viridian Therapeutics Announces Presentations at Multiple Medical Meetings in September

September 6, 2023

Viridian Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

August 7, 2023

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

August 3, 2023

Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

July 9, 2023

Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Endocrine Society

June 12, 2023

Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 8, 2023

Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections

May 7, 2023

Viridian Therapeutics to Webcast First Quarter 2023 Financial Results and Corporate Update on May 9, 2023

May 1, 2023

Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology

April 19, 2023

Viridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer

April 11, 2023

Viridian Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates

March 7, 2023

Viridian Therapeutics Announces Presentations at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society

March 6, 2023

Viridian Therapeutics to Webcast Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023

February 28, 2023

Viridian Therapeutics to Participate in Cowen’s 43rd Annual Health Care Conference

February 27, 2023

Viridian Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference

February 6, 2023

Viridian Appoints Scott Myers as President and Chief Executive Officer

February 5, 2023

Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED)

January 7, 2023

Viridian Therapeutics to Webcast Presentation at the 41st Annual J.P. Morgan Healthcare Conference

January 2, 2023

Calls in 2023

Decks in 2023